There is an urgent need for new strategies to treat invasive fungal infections, which are a leading cause of human mortality. Here, we establish two activities of the natural product beauvericin, which potentiates the activity of the most widely deployed class of antifungal against the leading human fungal pathogens, blocks the emergence of drug resistance, and renders antifungal-resistant pathogens responsive to treatment in mammalian infection models. Harnessing genome sequencing of beauvericin-resistant mutants, affinity purification of a biotinylated beauvericin analog, and biochemical and genetic assays reveals that beauvericin blocks multidrug efflux and inhibits the global regulator TORC1 kinase, thereby activating the protein kinase CK2 and inhibiting the molecular chaperone Hsp90. Substitutions in the multidrug transporter Pdr5 that enable beauvericin efflux impair antifungal efflux, thereby impeding resistance to the drug combination. Thus, dual targeting of multidrug efflux and TOR signaling provides a powerful, broadly effective therapeutic strategy for treating fungal infectious disease that evades resistance.

Shekhar Guturja, T., Gunaherath, G., Wijeratne, E., Lambert, J., Averette, A., Lee, S., et al. (2016). Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. NATURE CHEMICAL BIOLOGY, 12(10), 867-875 [10.1038/nchembio.2165].

Dual action antifungal small molecule modulates multidrug efflux and TOR signaling

TRIPODI, FARIDA;COCCETTI, PAOLA;
2016

Abstract

There is an urgent need for new strategies to treat invasive fungal infections, which are a leading cause of human mortality. Here, we establish two activities of the natural product beauvericin, which potentiates the activity of the most widely deployed class of antifungal against the leading human fungal pathogens, blocks the emergence of drug resistance, and renders antifungal-resistant pathogens responsive to treatment in mammalian infection models. Harnessing genome sequencing of beauvericin-resistant mutants, affinity purification of a biotinylated beauvericin analog, and biochemical and genetic assays reveals that beauvericin blocks multidrug efflux and inhibits the global regulator TORC1 kinase, thereby activating the protein kinase CK2 and inhibiting the molecular chaperone Hsp90. Substitutions in the multidrug transporter Pdr5 that enable beauvericin efflux impair antifungal efflux, thereby impeding resistance to the drug combination. Thus, dual targeting of multidrug efflux and TOR signaling provides a powerful, broadly effective therapeutic strategy for treating fungal infectious disease that evades resistance.
Articolo in rivista - Articolo scientifico
Molecular Biology; Cell Biology, antifungal small molecule, CK2 pathway,TOR signaling
English
867
875
9
Shekhar Guturja, T., Gunaherath, G., Wijeratne, E., Lambert, J., Averette, A., Lee, S., et al. (2016). Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. NATURE CHEMICAL BIOLOGY, 12(10), 867-875 [10.1038/nchembio.2165].
Shekhar Guturja, T; Gunaherath, G; Wijeratne, E; Lambert, J; Averette, A; Lee, S; Kim, T; Bahn, Y; Tripodi, F; Ammar, R; Döhl, K; Niewola Staszkowska, K; Schmitt, L; Loewith, R; Proth, F; Sanglard, D; Andes, D; Nislow, C; Coccetti, P; Gingras, A; Heitman, J; Gunatilaka, A; Ecowen, L
File in questo prodotto:
File Dimensione Formato  
Tanvi et al 2016.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 1.91 MB
Formato Adobe PDF
1.91 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/138397
Citazioni
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 54
Social impact